$TELO News

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company

Telomir Pharmaceuticals Announces ~$5.6M Investment In PIPE Financing Through Common Stock Issuance

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

Maxim Group Initiates Coverage On Telomir Pharmaceuticals with Buy Rating, Announces Price Target of $4

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

Telomir Announces New Research Findings From Ohio State University College Of Veterinary Medicine Showing Telomir-Zn Produces Inhibition Of Cell Growth Across Human And Canine Osteosarcoma Models

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Telomir Pharmaceuticals Publishes Peer-Reviewed Preclinical Data In Biomedicine & Pharmacotherapy Titled "Telomir-Zn Restores Glucose Homeostasis and Reduces Insulin Resistance in a Diet-Induced Zebrafish Model of Type 2 Diabetes"

Telomir Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichselbaum, Effective June 6, 2026

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

Telomir Pharma Announces Peer-Reviewed Publication Of Preclinical Data Showing Telomir-Zn Produced Dose-Dependent Survival Improvement Across Multiple Endpoints In Wilson's Disease Model

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

Telomir Pharmaceuticals Submits Investigational New Drug Application To FDA To Treat Advanced And Metastatic Triple-Negative Breast Cancer

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Telomir Reveals New Data Showing Broad Tumor Cell Mortality In Distinct Triple-Negative Breast Cancer

Telomir Reveals New Data Showing Broad Tumor Cell Mortality In Distinct Triple-Negative Breast Cancer